You are here

Michele Maio (IT)

Dr. Michele Maio is Director of the Division of Medical Oncology and Immunotherapy at the University Hospital of Siena ‐ Department of Oncology, Lecturer in Immunology at the Medical School of Udine, and Adjunct Professor at the College of Science and Biotechnology at Temple University. Dr. Maio received his MD from the 2nd School of Medicine in Naples. He is board certified in Oncology and Hematology, and is licensed as full Professor of Oncology.
Dr. Maio’s research interests include cancer immunobiology and epigenetics, as well as bioimmunotherapy of solid tumors. He has authored more than 250 publications in books, monographs, and peer‐reviewed Journals including Lancet, Lancet Oncology, New England Journal of Medicine, Journal of Clinical Investigation, Human Gene Therapy, Journal of Translational Medicine, Blood, Breast Cancer Research and Treatment, Cancer Research, Cancer Immunology Immunotherapy, Journal of Clinical Oncology, and Clinical Cancer Research.
Dr. Maio serves on Editorial Boards for Seminars in Oncology, Journal of Immunotherapy, Women’s Oncology Reviews, Journal of Translational Medicine, Journal of Experimental and Clinical Cancer Research, and Supportive and Palliative Cancer Care.
Dr. Maio is funding member and President of the Italian Network for Tumor Biotherapy (NIBIT) and he is President of the NIBIT Foundation.
Dr. Maio has served/serves on Advisory Boards, Steering and Scientific Committees for different Pharmaceuticals including: BMS, GSK, Roche, MSD, AZ, MedImmune, Amgen, Merck Serono, Epigen Therapeutics, Sigma‐tau, Novartis, Pierre Fabre, Astex Pharmaceuticals, Pfizer.
Dr. Maio has supervised more than 20 MD and PhD theses. His preclinical and clinical research activities are supported by national and international granting bodies. Lastly, Dr. Maio is/has been Principal Investigator and national Coordinator of more than 100 phase I‐III clinical trials.